Descovy and Truvada are equally effective at preventing HIV, but they differ in side effects, cost, and who can use them. Neither is universally “better.” The right choice depends on your body, your budget, and how you plan to take PrEP.
Both drugs combine emtricitabine with a form of tenofovir. Truvada uses an older version called TDF, while Descovy uses a newer formulation called TAF. That one difference in chemistry drives nearly every practical distinction between the two.
HIV Prevention: Equally Effective
The head-to-head comparison comes from the DISCOVER trial, which followed over 5,300 men and transgender women for 96 weeks. Among those taking Descovy, 8 acquired HIV (a rate of 0.16 per 100 person-years). Among those taking Truvada, 15 acquired HIV (0.30 per 100 person-years). That might look like Descovy performed better, but the difference wasn’t statistically significant. The trial confirmed that Descovy is non-inferior to Truvada, meaning it works just as well. Both drugs provide extremely high protection when taken consistently.
Where Descovy Has an Edge: Bones and Kidneys
The clearest advantage Descovy holds is in bone and kidney safety. Truvada’s older tenofovir formulation circulates at higher levels in the blood, which can stress the kidneys and pull minerals from bone over time. Descovy’s newer formulation delivers the drug more directly to target cells, reducing exposure elsewhere in the body.
In the DISCOVER trial, bone mineral density declines of 5% or more at the lumbar spine occurred in 4% of Descovy users versus 16% of Truvada users at 96 weeks. At the hip, the differences were smaller but still favored Descovy. For most young, healthy people, Truvada’s bone effects are modest and reversible after stopping the drug. But if you already have low bone density, kidney concerns, or other risk factors, Descovy may be the safer long-term option.
Where Truvada Has an Edge: Weight and Cholesterol
Descovy is associated with more weight gain and less favorable cholesterol changes. In a study of nearly 700 patients who switched to a regimen containing Descovy’s tenofovir formulation, average weight increased by 1.75 kg (about 3.9 pounds) over 48 weeks, significantly more than the 0.54 kg gained in the prior 48 weeks on their old regimen. Triglycerides rose by an average of 63 mg/dL, and total cholesterol increased by about 22 mg/dL.
These metabolic shifts are generally mild for most people, but they matter if you’re already managing high cholesterol or are concerned about cardiovascular risk. Truvada tends to have a more neutral or even slightly favorable effect on lipids.
Descovy Is Not Approved for Everyone
This is one of the most important distinctions. The FDA approved Descovy for PrEP with a notable exclusion: it is not indicated for people at risk of HIV through receptive vaginal sex. The DISCOVER trial enrolled only cisgender men and transgender women who have sex with men, so there’s simply no clinical data proving Descovy works for vaginal exposure. Truvada, by contrast, has been studied and approved for all adults at risk, including cisgender women.
If you’re a cisgender woman or a transgender man who may be exposed to HIV through vaginal sex, Truvada (or the injectable option, cabotegravir) is the appropriate choice. Descovy isn’t an option in that scenario.
On-Demand Dosing Only Works With Truvada
Some people prefer taking PrEP only around the times they have sex rather than every day. This approach, called 2-1-1 or event-driven dosing, involves taking two pills 2 to 24 hours before sex, one pill 24 hours later, and one pill 48 hours after that. It was studied in the IPERGAY trial and is prescribed off-label for men who have sex with men, particularly those who have sex infrequently and can plan ahead.
This dosing strategy has only been studied with Truvada. The CDC notes it can be prescribed to men who have sex with men using Truvada, though it is not FDA-approved or formally recommended. Descovy has no data supporting on-demand use. If daily pill-taking doesn’t fit your life and you’d prefer event-driven dosing, Truvada is the only oral PrEP with evidence behind that approach.
Cost Differences Are Significant
Truvada’s patent has expired, which means generic versions are widely available and far less expensive. Descovy remains patent-protected until 2032, keeping it at brand-name pricing. The practical difference can be substantial depending on your insurance, copay assistance programs, or whether you’re paying out of pocket.
Many PrEP assistance programs and manufacturer copay cards can reduce or eliminate costs for either drug. But when coverage is limited or you’re navigating insurance gaps, generic Truvada is significantly cheaper. For health systems and public health programs working to expand PrEP access, the cost difference makes generic Truvada the default in many settings worldwide.
How to Choose Between Them
If you’re a cisgender man or transgender woman with no major kidney or bone concerns, generic Truvada is effective, well-studied, and affordable. It’s been the backbone of PrEP since 2012 and has prevented countless infections. For most people, it remains the practical first choice.
Descovy makes more sense if you have existing kidney problems, reduced bone density, or risk factors that make Truvada’s side effect profile less ideal. It delivers the same HIV protection with a gentler impact on those organ systems. The tradeoff is higher cost and a slight tendency toward weight gain and cholesterol increases.
If you’re a cisgender woman, the decision is already made for you: Truvada or injectable PrEP, since Descovy lacks the data for vaginal exposure. And if you want the flexibility of on-demand dosing, Truvada is the only oral option with clinical evidence supporting that approach.